Deep tech, round 2: DCVC Bio bags $350M fund to chase the tip of the life sci­ence spear

It took one trip from San Fran­cis­co to Van­cou­ver for Kier­sten Stead and her DCVC Bio crew to feel con­fi­dent about throw­ing their weight — and cash — be­hind Ab­Cellera.

CEO Carl Hansen’s aca­d­e­m­ic back­ground and the po­ten­tial of the plat­form, which com­bined ma­chine vi­sion and ro­bot­ics with mi­croflu­idics, were promis­ing. But the site vis­it sealed the Se­ries A deal, where DCVC was the lead and on­ly in­vestor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER